Last reviewed · How we verify
Prevacid (lansoprazole)
Irreversibly inhibits the gastric proton pump to suppress acid secretion.
Lansoprazole (Prevacid) is a proton pump inhibitor approved in 1995, developed by Takeda. Now available OTC and generically, it provides effective acid suppression with rapid onset of action.
At a glance
| Generic name | lansoprazole |
|---|---|
| Also known as | Prevacid, Zoton |
| Sponsor | Generic (originally Takeda) |
| Drug class | Proton pump inhibitor (PPI) |
| Target | ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1995-05-10 (United States) |
Mechanism of action
Lansoprazole is a PPI with rapid onset of action, typically providing symptom relief within 1-3 days. Available in an orally disintegrating tablet formulation useful for patients with swallowing difficulties.
Approved indications
- Duodenal Ulcer due to H. Pylori
- Duodenal ulcer disease
- Erosive esophagitis
- Gastric Hypersecretory Conditions
- Gastric ulcer
- Gastroesophageal reflux disease
- Maintenance of Healing Duodenal Ulcer
- NSAID-Induced Gastric Ulcer
- Peptic ulcer
- Zollinger-Ellison syndrome
Common side effects
- Diarrhea
- Abdominal pain
- Nausea
- Constipation
Serious adverse events
- Myocardial infarction
- Cerebrovascular accident/cerebral infarction
- Gastrointestinal hemorrhage
- Hematemesis
- Melena
- Esophageal ulcer
- Esophageal stenosis
- Shock (circulatory failure)
- Syncope
- Carcinoma
Key clinical trials
- A Multi-center, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer (Phase 3)
- A Single Center, Open Label, Randomized, Single-dose, Two-period, Two-way Cross-over Study to Compare the Rate and Extent of Absorption of DelanzoᵀᴹDR 60mg (Dexlansoprazole) Capsule With Dexilant® 60m (Phase 1)
- A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Two-Period, Two-Part Crossover Study in Healthy Subjects to Compare the Bioavailability of Dexlansoprazole From Dexlansoprazole Delayed-R (Phase 1)
- Effect of Proton Pump Inhibitor on Prevention of Tumor Bleeding in Patients Under Palliative Chemotherapy for Unresectable Gastric Cancer: a Randomized, Double Blind, and Placebo Controlled Multicente (Phase 3)
- Prospective, Randomized Controlled Trial Comparing Amoxicillin and Metronidazole Based Bismuth-containing Quadruple Therapy With Amoxicillin and Clarithromycin Based Quadruple Therapy for First-line H (Phase 4)
- A Randomized Controlled Study on the Efficacy and Safety of Gut-Brain Neuromodulators in Patients With Gastroesophageal Reflux Disease (NA)
- Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding (Phase 4)
- A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis (Phase 3)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 11077055 | 2036-04-21 | Formulation |
| 11986554 | 2036-04-21 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prevacid CI brief — competitive landscape report
- Prevacid updates RSS · CI watch RSS
- Generic (originally Takeda) portfolio CI